Gary Charles Robb - Jan 2, 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb.
Stock symbol
CORT
Transactions as of
Jan 2, 2025
Transactions value $
-$509,370
Form type
4
Date filed
1/6/2025, 07:15 PM
Previous filing
Dec 4, 2024
Next filing
Mar 4, 2025

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -11K -78.36% $0.00 3.04K Jan 2, 2025 Common Stock 11K $3.29 Direct F5
transaction CORT Stock option (right to buy) Options Exercise $0 -3.04K -100% $0.00 0 Jan 3, 2025 Common Stock 3.04K $3.29 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 This transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
F3 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.39 to $50.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F4 These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
F5 Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.